Visiongain Publishes Antibody Drug Conjugates Market Report 2021-2031

11 November 2020
Pharma

Visiongain has published a new report on Antibody Drug Conjugates Market Report 2021-2031: Forecasts by Technology (Cleavable Linkers, Non-Cleavable Linkers, Other Technology), by Payload Type (MMAE, DM4, Camptothecin, DM1, MMAF, Other Payload Type), by Target Antigen (CD30, HER2, CD22, CD33), by Drug Type (Adcetris, Kadcyla, Other Drugs), by Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Application), by Linker Type (VC, VA, SMCC, Hydrazone, Other Linker Type). PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped) AND Profiles of Leading Companies, Region and Country.

Visiongain has estimated that the total market for Antibody Drug Conjugates would be around $xx billion in 2020 and is projected to grow at a CAGR of xx% during the forecast period 2021-2031. The market is estimated to grow at a CAGR of xx% in the first half period 2021-2026 and is projected to grow at CAGR of xx% in the other half period 2026-2031. Antibody drug conjugate (ADC) technology continues to evolve as a widely successful drug targeting technology for the treatment of cancer. Enormous progress has been made by researchers in the development of ADC constituents. Advances in targeting antibodies, potent payloads and drug-linker technologies that facilitate improved ADC stability, potency and targeting efficiency led to the development of ten commercially viable ADCs. ADCs are the next-generation treatment for various kinds of cancers. With two approved products and many in clinical trials, ADC development has become one of the most attractive classes of biologics.

Increase in Number of Cancer Patients in the World is Creating Opportunities for Cancer Diagnostic Compaanies
Oncotic, with spending over US$ 100 trillion in major developed and pharmaceutical markets, is the leading class in specialty medicines by 2020. Of the $298 billion growth of developing-market brands by 2020, $135 billion are the product of new medicines, with the largest proportion coming from oncology medicinal products launched over the next five years. These treatments often take years to reach patients outside the main developed markets, which means that the range of innovations will be less widespread in the next five years. The new medicines available are increasingly being used to treat oncology and orphan conditions and to offer a range of specialty molecular medicines.

Other Factors Boosting the Market Growth
• Use of known or approved antibodies and cytotoxins in ADCs means potentially streamlined reviews and briefer development cycles.
• Technological advances, including stable linker technologies, have provided the impetus to develop more targeted and efficacious ADCs.
• Development of more stable linkers and potent cytotoxins are likely to ensure that the next generation ADCs have an improved safety/efficacy profile.
• Increasing incidence of cancer is also contributing to the development of ADCs.

Is Complexity of ADCs hindering its Growth?
Manufacturing an ADC is a complex process. It requires a small molecule, an antibody, chemical linking chemistry and different amino acid conjugation. Antibody drug conjugates exhibit a more complex and heterogeneous structure than the parent monoclonal antibody. This complexity and heterogeneity present a significant challenge for generic manufacturers to copy the ADCs; thus, the complexity of ADCs preserves companies’ investment longer.

Leading companies and the potential for market growth
AbbVie Inc.
Astellas Pharma Inc
Bayer Pharmaceuticals
Celldex Therapeutics, Inc.
Genentech Biotechnology
ImmunoGen Biotechnology
Immunomedics Inc
Lonza Group AG (Lonza)
Mersana Therapeutics Inc.
Takeda Pharmaceutical Company Limited
Roche Holding AG (Roche)
Pfizer Inc. (Pfizer)
Lantheus Holdings, Inc.
Seattle Genetics, Inc.
Merck KGaA

Overall world revenue for Antibody Drug Conjugates Market will surpass $xx billion in 2020, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

Key Questions Answered in the report
• What are the best investment options for venturing into new product and service lines?
• What value proposals should businesses aim at while providing new funding for research and development?
• Which regulations will be most useful for stakeholders to enhance their supply chain network?
• Which regions could see demand ripening in certain segments in the near future?
• What are some of the best cost optimization strategies with vendors that some well-trained players have been successful with?
• What are the key perspectives that C-suite is leveraging to move businesses to a new growth trajectory?
• Which government regulations could call into question the status of key regional markets?
• How will the emerging political and economic scenario affect opportunities in key areas of growth?
• What are some of the value-added opportunities in different segments?
• What will be the barriers to entry for new players on the market?

The comprehensive report offers market estimation and forecast for the period ranging 2021 – 2031 for leading national markets and rest of the world. Moreover, the report contains dedicated leading companies covering 10 leading producers in the field of Antibody Drug Conjugates.

The Antibody Drug Conjugates Market Report 2021-2031 report will be of value to anyone who wants to better understand the market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biological Imaging Reagents Market Report 2021-2031

Increasing prevalence of cardiovascular diseases is increasing demand of biological imaging reagents for the diagnosis and treatment of cardiovascular diseases due to this reason increasing prevalence of cardiovascular diseases is acting as a driver for biological imaging reagent market.

13 November 2020

Read

Visiongain Publishes Antihypertensive Drugs Market Report 2021-2031

Hypertensive is the most common disease around the world. However, number of people suffering from hypertensive has increased very significantly from last few years. Hypertensive can occur due to consumption of tobacco, too much salt (sodium) and little potassium in your diet, alcohol and to people being overweight or obese.

13 November 2020

Read

Visiongain Publishes Antibacterial Drugs Market Report 2021-2031

The prevalence of bacterial diseases is significantly growing and expected to continuously rise over the forecast period. Number of bacterial diseases cases are increasing, like, bugs biting, including ticks, mosquitoes, lice and from an infected animal, contaminated food or water.

13 November 2020

Read

Visiongain Publishes Topical Drug Delivery Market Report 2020-2030

Delivery of biologics through the transdermal route is anticipated to open new avenues for the manufacturers of topical drugs. Transdermal route provides appropriate and painless self-administration for patients. It overcomes frequent dosing administration, plasma level instability related to oral dosing and injections to uphold constant drug concentrations, and a drug with a short half-life can be supplied effortlessly.

11 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever